Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Yingxin Sun; Yifeng Cai; Jia Chen; Jiannong Cen; Mingqing Zhu; Jinlan Pan; Depei Wu; Aining Sun; Suning Chen

doi:10.3389/fonc.2021.753842

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Front Oncol. 2021 Oct 11:11:753842. doi: 10.3389/fonc.2021.753842. eCollection 2021.

Authors

Yingxin Sun^{1

2}, Yifeng Cai³, Jia Chen^{1

2}, Jiannong Cen^{1

2}, Mingqing Zhu^{1

2}, Jinlan Pan^{1

2}, Depei Wu^{1

2}, Aining Sun^{1

2}, Suning Chen^{1

2}

Affiliations

¹ Department of Hematology, First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Soochow University, Suzhou, China.
² Department of Thrombosis and Hemostasis, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
³ Department of Hematology, The Affiliated Hospital of Nantong University, Nantong University, Nantong, China.

Abstract

Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but the efficacy is variable. Here, we report two patients diagnosed with MPN with PCM1-JAK2 fusion who were treated with ruxolitinib-based regimen, including the first case of ruxolitinib combined with pegylated interferon (Peg-IFN), and we conduct a literature review. We found that ruxolitinib combined with Peg-IFN is an effective treatment option in the case of poor efficacy of ruxolitinib monotherapy.

Keywords: PCM1-JAK2; case report; myeloproliferative neoplasms; pegylated interferon; ruxolitinib.

Publication types

Case Reports